280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Investor Presentation
Reports Year End 2025 Financial Results and Highlights
Alumis Inc. Reports Preliminary Cash of $308.6 Million as of December 31, 2025
Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
Other Events
Earnings Release
FY 2025
Q3
Q2
Q1
Amended Annual Report
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus Filed Pursuant to Rule 425
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report